Advertisement
Research Article

In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile

  • Michael J Sorich equal contributor,

    equal contributor Contributed equally to this work with: Michael J Sorich, Nicolas Pottier

    Affiliations: Hematological Malignancies Program and the Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America, Sansom Institute, University of South Australia, Adelaide, Australia

    X
  • Nicolas Pottier equal contributor,

    equal contributor Contributed equally to this work with: Michael J Sorich, Nicolas Pottier

    Affiliations: Hematological Malignancies Program and the Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America, EA2679, Faculté de Médecine de Lille, Pole Recherche, Lille, France

    X
  • Deqing Pei,

    Affiliation: Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America

    X
  • Wenjian Yang,

    Affiliation: Hematological Malignancies Program and the Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America

    X
  • Leo Kager,

    Affiliations: Hematological Malignancies Program and the Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America, Department of Hematology-Oncology, St. Anna Children's Hospital, Vienna, Austria

    X
  • Gabriele Stocco,

    Affiliations: Hematological Malignancies Program and the Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America, Instituto di Ricovero e Cura a Carattere Scientifico, Burlo Garofolo and University of Trieste, Trieste, Italy

    X
  • Cheng Cheng,

    Affiliation: Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America

    X
  • John C Panetta,

    Affiliations: Hematological Malignancies Program and the Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America, University of Tennessee, Memphis, Tennessee, United States of America

    X
  • Ching-Hon Pui,

    Affiliations: University of Tennessee, Memphis, Tennessee, United States of America, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America

    X
  • Mary V Relling,

    Affiliations: Hematological Malignancies Program and the Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America, University of Tennessee, Memphis, Tennessee, United States of America, Pharmacogenetics of Anticancer Agents Research Group, National Institutes of Health Pharmacogenetics Research Network, Memphis, Tennessee, United States of America, and Chicago, Illinois, United States of America

    X
  • Meyling H Cheok,

    Affiliations: Hematological Malignancies Program and the Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America, University of Tennessee, Memphis, Tennessee, United States of America

    X
  • William E Evans mail

    To whom correspondence should be addressed. E-mail: william.evans@stjude.org

    Affiliations: Hematological Malignancies Program and the Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America, University of Tennessee, Memphis, Tennessee, United States of America, Pharmacogenetics of Anticancer Agents Research Group, National Institutes of Health Pharmacogenetics Research Network, Memphis, Tennessee, United States of America, and Chicago, Illinois, United States of America

    X
  • Published: April 15, 2008
  • DOI: 10.1371/journal.pmed.0050083

About the Authors

Michael J Sorich, Nicolas Pottier, Wenjian Yang, Leo Kager, Gabriele Stocco, John C Panetta, Mary V Relling, Meyling H Cheok, William E Evans
Hematological Malignancies Program and the Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America
Michael J Sorich
Sansom Institute, University of South Australia, Adelaide, Australia
Nicolas Pottier
EA2679, Faculté de Médecine de Lille, Pole Recherche, Lille, France
Deqing Pei, Cheng Cheng
Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America
Leo Kager
Department of Hematology-Oncology, St. Anna Children's Hospital, Vienna, Austria
Gabriele Stocco
Instituto di Ricovero e Cura a Carattere Scientifico, Burlo Garofolo and University of Trieste, Trieste, Italy
John C Panetta, Ching-Hon Pui, Mary V Relling, Meyling H Cheok, William E Evans
University of Tennessee, Memphis, Tennessee, United States of America
Ching-Hon Pui
Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America
Mary V Relling, William E Evans
Pharmacogenetics of Anticancer Agents Research Group, National Institutes of Health Pharmacogenetics Research Network, Memphis, Tennessee, United States of America, and Chicago, Illinois, United States of America

Corresponding Author

Email: william.evans@stjude.org

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

MJS, C-HP, MHC, and WEE designed the experiments and the study. MJS, DP, WY, GS, CC, JCP, MVR, WEE, and MHC analyzed the data. C-HP enrolled and treated patients. NP wrote the first draft of the paper. MJS, WY, LK, GS, CC, C-HP, MVR, MHC, and WEE contributed to writing the paper. MHC collected gene expression and patient data for this study.